CanSino Biologics Inc (CanSino Biologics) is a biopharmaceutical company that develops, manufactures and commercializes pneumococcal, polyvalent conjugate and adenovirus-based recombinant TB vaccines. The company is investigating Ad5-EBOV, an adenovirus type 5 vector, to treat Ebola virus, MCV2 and MCV4 vaccines for the prevention of Neisseria meningitidis bacteria. It is also evaluating DTcP vaccine against pertussis caused after primary vaccination in infants and children and PBPV, PCV13i vaccines, targeting pneumococcal diseases. CanSino Biologics utilizes Adenovirus-based viral vector vaccine, conjugation, formulation and protein structure design and recombinant technology to develop vaccines. The company works in partnership with MC Master University, National Research Council of Canada and Beijing Institute of Biotechnology. CanSino Biologics is headquartered in Tianjin, China.
Headquarters
China
Address
West District Biomedical Park, No. 185, South Avenue, West District, Economic, Tianjin, 300457
Website
www.cansinotech.com.cn
Telephone
86 22 58213766
No of Employees
1,494
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
6185 (HKG)
Revenue (2022)
$48.8M
-66.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-63%
(2022 vs 2021)
Market Cap*
$1.1B
Net Profit Margin (2022)
XYZ
-387.0%
(2022 vs 2021)
* As of and is in US$
CanSino Biologics Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Pipeline | Research and Development | Menphecia |
| Ad5-EBOV: Ebola Virus | Menhycia | |
| MCV2 and MCV4: | Convidecia | |
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In December, the company signed an agreement with Saudi Pharmaceutical Industries and Medical Appliances Corporation on innovative vaccines to boost access to critical biopharmaceuticals. |
| 2023 | Plans/Strategy | In August, the company announced its plans to acquire 10% stake in Solution Group. |
| 2023 | Contracts/Agreements | In August, the company partnered with 3D Medicines to facilitate the joint efforts of both parties in developing next-generation mRNA cancer vaccines. |
Competitor Comparison
| Key Parameters | CanSino Biologics Inc | Chongqing Zhifei Biological Products Co Ltd | Sino Biopharmaceutical Ltd | Sinovac Biotech Ltd | Beijing Tiantan Biological Products Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | China |
| City | Tianjin | Chongqing | Hong Kong | Beijing | Beijing |
| State/Province | Tianjin | Chongqing | - | Beijing | Beijing |
| No. of Employees | 1,494 | 5,735 | 25,806 | 3,558 | 4,858 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Xuefeng Yu., Ph.D. | Chairman; Director; General Manager; Chief Executive Officer | Executive Board | 2009 | 59 |
| Shou Bai Chao, Ph.D. | Director; Chief Operating Officer | Executive Board | 2018 | 60 |
| Tao Zhu., Ph.D. | Chief Scientific Officer; Deputy General Manager; Director | Executive Board | 2009 | 50 |
| Dongxu Qiu, Ph.D. | Deputy General Manager; Executive Vice President; Director | Executive Board | 2009 | 63 |
| Jing Wang | Director; Chief Commercial Officer; Deputy General Manager | Executive Board | 2021 | 44 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward